Hepatobiology and Toxicology COBRE

肝脏生物学和毒理学 COBRE

• 批准号: 10377890
• 负责人: CRAIG J. MCCLAIN
• 金额: $ 230.96万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-06-10 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10377890
• 关键词: Acute Liver Failure; Address; Adult; Affect; Alcoholic Liver Diseases; American; Area; Basic Science; Biomedical Research; Centers of Research Excellence; Child; Cirrhosis; Collaborations; Communication; Communities; Complex; Core Facility; Data Analyses; Development; Diabetes Mellitus; Discipline; Drug Interactions; Drug abuse; Ensure; Environment; Enzymes; FDA approved; Fostering; Funding; Goals; Grant; Health; Hepatitis A; Hepatitis B; Hepatitis C; Home; Homelessness; Industrialization; Industry; Injury; International; Kentucky; Laboratories; Link; Liver; Liver Failure; Liver diseases; Mentors; Metabolic syndrome; Metabolism; Molecular Target; Morbidity - disease rate; National Institute on Alcohol Abuse and Alcoholism; Obesity; Organ; Overweight; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase I Clinical Trials; Prevention; Primary carcinoma of the liver cells; Process; Program Sustainability; Publications; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Scientist; Structure; Technology; Therapeutic; Toxic Environmental Substances; Toxicant exposure; Toxicology; Translational Research; United States National Institutes of Health; Universities; University resources; biobank; career development; clinical practice; drug induced liver injury; education research; experience; liver injury; liver transplantation; member; multidisciplinary; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel therapeutics; nutrition; personalized medicine; prevent; programs; recruit; success; toxicant; viral liver disease

The University of Louisville (UofL) Hepatobiology and Toxicology (H&T) COBRE is a unique thematic center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic strategies for multiple forms of liver disease/injury, including: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis—the most common liver disease in the US/worldwide, and is highly linked to the metabolic syndrome; Alcoholic Liver Disease—a common problem among those who drink; Environmental Toxicant Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area; Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver; and Drug-Induced Liver Injury—the most common reason drugs are removed from the market and an important cause of liver failure. This COBRE brings together experienced senior mentors/investigators and promising junior investigators to perform cross-cutting research on the unique topics of Hepatobiology and Toxicology. We address critical barriers in our understanding of the development/ progression of liver disease and we define targets for prevention/treatment that could transform clinical practice. Specific Aims of the Hepatobiology and Toxicology COBRE are to: 1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology that helps build and sustain the overall research infrastructure at UofL. 2. Expand and strengthen the multidisciplinary program in research education, mentoring and career development in Hepatobiology and Toxicology, and systematically track and evaluate the progress. 3. Provide the necessary research resources and translational science/basic technologies to support state-of- the-art research in Hepatobiology and Toxicology and to ensure sustainability of the program. 4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver diseases/toxicant exposures and communicate our findings to the public. In summary, Phase I strengthened UofL’s biomedical research infrastructure through the establishment of a thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to compete for independent funding. In Phase I, we met or exceeded our metrics, including 1) four of our investigators transitioning to independent research funding; 2) 91 mentee and 162 total publications; 3) new renovated laboratory space; 4) numerous presentations; 5) establishing new collaborations; and 6) >$75 million in total new grant funding by H&T members. This Phase II proposal builds on our Phase I success, extends and strengthens the scope of the program, and provides a roadmap for sustainability.

路易斯维尔大学（UofL）肝脏生物学和毒理学（H&T）COBRE是一个独特的主题 中心专注于肝脏研究。UofL H&T COBRE专注于机制和治疗 多种形式的肝脏疾病/损伤的策略，包括：非酒精性脂肪肝/非酒精性 脂肪性肝炎-美国/世界范围内最常见的肝脏疾病，与代谢性肝炎密切相关。 综合征;酒精性肝病-饮酒者的常见问题;环境毒物 诱导性肝损伤-一个日益被认识到的问题，路易斯维尔一直是这方面的领导者; B型和C型肝炎-全球肝硬化和肝细胞癌的重要原因;个性化 药物--药物疗效越来越重要的因素，而大多数药物在肝脏代谢; 和药物性肝损伤-最常见的原因药物从市场上撤下， 肝衰竭的重要原因这个COBRE汇集了经验丰富的高级导师/调查员， 有前途的初级研究人员对肝脏生物学的独特主题进行交叉研究， 毒理学。我们解决了我们对肝病发展/进展的理解中的关键障碍 我们确定了预防/治疗的目标，这可能会改变临床实践。 肝脏生物学和毒理学COBRE的具体目标是： 1.扩大和加强肝脏生物学和毒理学的主题为重点的计划，帮助建立 并维持UofL的整体研究基础设施。 2.扩大和加强研究教育，指导和职业生涯的多学科计划 发展，并系统地跟踪和评估进展。 3.提供必要的研究资源和转化科学/基础技术，以支持国家 在肝脏生物学和毒理学的最先进的研究，并确保该计划的可持续性。 4.发现预防和/或治疗肝脏疾病的新机制/分子靶点和有效方法 疾病/有毒物质暴露，并将我们的发现传达给公众。 总之，第一阶段通过建立以下项目加强了UofL的生物医学研究基础设施： 肝脏生物学和毒理学的主题多学科中心，以提高研究人员的能力， 争取独立融资。在第一阶段，我们达到或超过了我们的指标，包括1）我们的四个 研究人员过渡到独立的研究资金; 2）91名学员和162个总出版物; 3）新的 翻新的实验室空间; 4）大量的演示; 5）建立新的合作; 6）> 75美元 亿美元的新赠款资金由H&T成员。第二阶段的提案建立在我们第一阶段的成功基础上， 扩展和加强了该计划的范围，并提供了可持续发展的路线图。